Vigilant Biosciences, Inc., has entered into a three-year exclusive sales and marketing agreement with Biotech-IgG AB for the distribution of the OncAlert Oral Cancer Risk Assessment System in Denmark, Norway and Sweden. The OncAlert Oral Cancer Risk Assessment System includes a rapid, point-of-care risk assessment test (OncAlert POC Test) and a quantitative, laboratory test (OncAlert LAB Assay).
Under the terms of the agreement, Biotech-IgG AB will exclusively market and sell the OncAlert POC Test and OncAlert LAB Assay to the dental and oncology markets in Scandinavia, pursuant to the CE Mark registration approvals of the products, which are expected in Q2 2015. Financial terms were not disclosed.
“We are pleased to be named the exclusive distributor of the OncAlert System in the Scandinavian market,” said Dario Kriz, Ph.D., CEO of Biotech-IgG AB. “This innovative, and effective system will enable healthcare professionals to more accurately and quickly assess the risk of oral cancer in their patients. There is currently no other solution on the market that takes this approach to oral cancer detection, and we are confident that it will help save lives.”
The OncAlert Oral Cancer Risk Assessment System is based on patented technology that detects specific protein markers known to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms. The simple, oral rinse procedure is easy to administer and non-invasive for the patient.
Source: PR News
